Agreements reached under this partnership
Discontinuation- 1
Our proprietary PRIME technology was applied to Adaptimmune's technology, and Adaptimmune conducted research and development related to TCR-T cell therapy technology.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The impact of this matter on our financial results for the fiscal year ending December 2026 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | Adaptimmune Limited |
| Alliance partner's business activities | Research and development of TCR-T cell therapy technology |
| Type of alliance | Discontinuation |
| Details of the alliance | Our proprietary PRIME technology was applied to Adaptimmune's technology, and Adaptimmune conducted research and development related to TCR-T cell therapy technology. |
| Alliance start date | August 2019 |
| Impact on Business Performance | The impact of this matter on our financial results for the fiscal year ending December 2026 is expected to be immaterial. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The two companies reached this decision after comprehensively considering the progress of research and development activities, Adaptimmune's development capacity, and the optimal allocation of our management and development resources. The companies state that the termination is not due to the safety or efficacy of the PRIME technology.